Stelara (ustekinumab) 130 mg, 1 vial, Cilag, Switzerland Stelara (ustekinumab) is used for approved inflammatory conditions including plaque psoriasis. International medicine delivery within 4-5 days with storage conditions maintained. Payment on delivery. Order at +380996042415 via Viber or WhatsApp.

Plaque Psoriasis

Treatment of moderate to severe plaque psoriasis in adults who have not responded to or are contraindicated or intolerant of other systemic therapies, including cyclosporine, methotrexate, or PUVA therapy.

Plaque psoriasis in children

Treatment of moderate to severe plaque psoriasis in children aged 12 years and older, whose condition is insufficiently controlled by other means of systemic therapy or phototherapy, or in case of intolerance to such treatment.

Psoriatic arthritis

As monotherapy or in combination with methotrexate for treatment of psoriatic arthritis in an active form in adults who have not had a positive effect from treatment with basic disease-modifying antirheumatic drugs (DMARDs).

Dozuvannya

Plaque psoriasis.

Prescribe an initial dose of 45 mg, the next dose of 45 mg is administered 4 weeks after the start of treatment, then every 12 weeks.

It is necessary to reconsider the advisability of continuing therapy in patients who do not have a therapeutic effect until the 28th week of treatment.

Patients with a body weight of more than 100 kg.

Patients with a body weight of more than 100 kg are prescribed an initial dose of 90 mg, the next dose of 90 mg is administered after 4 weeks, then every 12 weeks. For this group of patients, a dose of 45 mg may also be effective, but a dose of 90 mg provides greater efficacy.

Psoriatic arthritis.

An initial dose of 45 mg is prescribed, the next dose of 45 mg is administered after 4 weeks, then every 12 weeks. For patients weighing more than 100 kg, the starting dose may be 90 mg.

It is necessary to reconsider the advisability of continuing therapy in patients who do not have a therapeutic effect until the 28th week of treatment.